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Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), represent a family of RNA molecules that do not translate into
protein. Nevertheless, they have the ability to regulate gene expression and play an essential role in immune cell diﬀerentiation
and function. MicroRNAs were found to be diﬀerentially expressed in various tissues, and changes in their expression have been
associated with several pathological processes. Yet, their roles in systemic lupus erythematosus (SLE) and lupus nephritis (LN)
remain to be elucidated. Both SLE and LN are characterized by a complex dysfunction of the innate and adaptive immunity.
Recently, signiﬁcant ﬁndings have been made in understanding SLE through the use of genetic variant identiﬁcation and
expression pattern analysis and mouse models, as well as epigenetic analyses. Abnormalities in immune cell responses, cytokine
and chemokine production, cell activation, and apoptosis have been linked to a unique expression pattern of a number of
miRNAs that have been implicated in the immune pathogenesis of this autoimmune disease. The recent evidence that
signiﬁcantly increased the understanding of the pathogenesis of SLE drives a renewed interest in eﬃcient therapy targets. This
review aims at providing an overview of the current state of research on the expression and role of miRNAs in the immune
pathogenesis of SLE and LN.
1. Pathogenesis of Systemic
Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease characterized by a loss of tolerance against
nuclear autoantigens, lymphoproliferation, polyclonal auto-
antibody production, immune complex deposition, and
tissue inﬂammation [1]. SLE used to be referred to as a
complex autoimmune disease of unknown etiology; how-
ever, during the last decade, a multidisciplinary approach
to SLE-relevant research has built a more concise view of
the pathogenesis of the disease. SLE develops from a loss of
self-tolerance to ubiquitous autoantigens, which can be seen
as a result of a failed immunization process. This observation
implies two assumptions. First, autoreactive, long-lived
plasma cells and memory T cells memorize their immuniza-
tion against autoantigens. Second, the autoantigens must be
accessible to antigen-presenting cells (APCs), a process that
is normally avoided by various homeostatic mechanisms.
In fact, SLE develops in individuals with unfortunate com-
binations of genetic variants that, among other immuno-
regulatory defects, compromise those mechanisms that
normally assure low levels of autoantigens in extracellular
compartments (Figure 1). Overshooting activation of
antigen-presenting cells (APCs) turns the interpretation of
autoantigens from immune ignorance and lymphocyte
anergy into lymphocyte activation and proliferation, which
can overcome the functional unresponsiveness or anergy of
mature autoreactive B cells [2]. The “danger” hypothesis
model postulates that one of the sources of inﬂammation that
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Figure 1: Pathogenesis of systemic lupus erythematosus.
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may lead to autoimmunity is the generation of alarm sig-
nals by injured cells [3]. The injury that results from path-
ogens, toxicants, or trauma can trigger the release of the
so-called damage-associated molecular pattern (DAMP).
However, cells dying by any programmed and controlled cell
death do not activate APCs. The distinct responsiveness to
foreign-but-harmless (i.e., fetuses) and self-but-harmful
(i.e., certain mutations) materials needs to be extensively
studied in order to understand the development of autoin-
ﬂammatory and autoimmune diseases.
Multiple genetic and environmental factors are at play
during the development of SLE [4]. A few events including
a general tolerance break within adaptive immunity and the
overall innate immune system as well as local processes and
susceptibility factors within the organs seem to be crucial
for progression of SLE [5, 6]. The hallmark of SLE is the pres-
ence of autoantibodies directed against nuclear antigens,
which result in autoantibody-mediated end-organ damage
[5]. Numerous experimental studies show that various mice
strains exhibit a lack of immune tolerance to nuclear anti-
gens, resulting B cell hyperactivity and elevated number of
B cell subsets in the production of autoantibodies [7, 8].
Moreover, scientists observed increased number of autoreac-
tive T cells with increased expression of activation markers
on these cells [9, 10]. One of the important checkpoints is
the immune tolerance maintained by the adaptive immunity,
controlling autoreactive B cells and T cells [11]. The auto-
reactive cells are removed in the bone marrow (BM) and
thymus, respectively. In the thymus, the T cells undergo
negative selection to avoid the spreading of cells that recog-
nize self-antigens and to promote cells that tolerate one’s
own tissues. This process use antigen-presenting cells (APCs)
that present self-antigens to early-stage T cells [12]. There
should be no doubt that B cells play a crucial role in autoim-
mune reactions and their depletion may represent an eﬀec-
tive treatment of autoantibody-driven injuries [12]. Indeed,
it is not surprising that the number, activity, and elimination
of autoreactive B cells in the bone marrow (BM) or in periph-
eral lymphoid tissues can orchestrate the progression of SLE
[13, 14]. Another checkpoint consists of a universal form of
host defense referred as the innate immunity [15, 16]. These
mechanisms are important in maintaining acute inﬂamma-
tory responses to pathogenic and environmental stimuli such
as viruses or sterile inﬂammation. When this checkpoint fails
to function properly, peripheral autoinﬂammatory responses
may arise and consequently lead to development of autoanti-
bodies [17]. On the cellular level, especially peripheral
inﬂammation orchestrating myeloid cells and interferon-
producing pDCs were linked to SLE-phenotype and have a
strong impact on lupus pathogenesis [18]. Lack of homeo-
stasis within innate immune responses, chronic ongoing
inﬂammation, and impaired clearance of dead cells may ini-
tiate the severe tissue damage [19]. The consequence of dys-
regulation within these innate and adaptive immunity
checkpoints is the presence of autoantibodies, followed by
immune complexes, accumulation of T cells and myeloid
cells, and rising proinﬂammatory conditions. Moreover,
many other processes such as cell death, the clearance of
dead cells, antigen presentation, and adhesion of inﬁltrating
cells may determine susceptibility to tissue- or organ-speciﬁc
manifestation of lupus [18, 20–22].
2. Cells and Mechanisms Involved in the
Development of SLE
B cells are well-studied participants in the development of
SLE as well as other autoimmune diseases [23–25]. B lym-
phocyte stimulators such as B cell-activating factor (BAFF)
and a proliferation-inducing ligand (APRIL) regulate B cell
diﬀerentiation and Ig class switching [26] and promote
plasma cell survival [27]. Until now, they were predomi-
nantly considered as potential therapeutic targets in SLE
because the presence of autoantibodies is a hallmark feature
of many autoimmune diseases and autoantibody production
was thought to be the one and only role of B cells in SLE.
Among the autoantibodies found in SLE patients, some such
as anti-dsDNA and anti-Sm antibodies display particular
clinical and diagnostic importance and are highly speciﬁc
for SLE. Indeed, elimination of autoantibodies was unsuc-
cessful in a controlled clinical trial [28], and treatment of
some SLE patients with rituximab in order to deplete B cells
resulted in clinical improvement without aﬀecting anti-
dsDNA antibody levels [29]. Moreover, experimental studies
proved that antibody-deﬁcient mice still develop the SLE-like
disease and LN [23]. This fact may support another hypoth-
esis that, except B cells, other cells and local proinﬂammatory
eﬀects are involved in the development of the disease. Indeed,
various studies have shown that without the assistance of the
helper T lymphocytes, it is diﬃcult for the B cells alone
to trigger SLE pathogenicity. T cells possess the potential
to become key players in the development and progression of
SLE. Their capabilities to communicate with other cells of the
immune system are unique and need to be tightly regulated.
Interestingly, in comparison with healthy individuals, vari-
ous studies have shown that T cells isolated from patients
with SLE are abnormal, regarding both their phenotypes
and functions [30, 31]. Studies showed that the expansion
of the Th17 population and the downstream signaling of T
cell receptors (TCRs), as well as epigenetics, diﬀers in SLE
patients compared to healthy individuals. Additionally, the
function and number of regulatory T lymphocytes were dis-
tinct in SLE patients and healthy subjects [32–34] and immu-
nosuppressive therapies restored the number of functional
Tregs in patients with SLE [35–37]. In addition, high expres-
sion of CD40L detected on lupus T cells was responsible for
excessive stimulation of CD40 expressed on B cells. CD40
signaling triggers the production of autoantibodies, which
supports the hypothesis that SLE is a T cell-related disease.
Also, innate immunity responses represented by dendritic
cells and macrophages play an important role in the develop-
ment of SLE. Antigen-presenting cells (APCs) are essential in
establishing and maintaining peripheral tolerance as well as
in the regulation of immune responses. This is accomplished
via diverse regulatory mechanisms that regulate inﬂamma-
tion. Furthermore, they are responsible for the clearance of
dying cells. An increased level of apoptotic material was asso-
ciated with the incidence of SLE and the disease severity [38].
Several antigens released from the dying cells can result from
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increased cell death and/or insuﬃcient clearance of dying
cells. APCs are distributed in the tissues for optimal antigen
capture. They have the capacity to process antigens and pres-
ent antigens to T cells. This process results in anergy or elim-
ination of self-reactive T cells and the development of
regulatory T cells [39]. Apart from the functions mentioned
above, it is possible that overshooting immune responses of
classically activated inﬂammatory macrophage responses
induce the imbalanced macrophage signaling and lead to
the runaway inﬂammation that is one of the crucial features
of SLE [40]. Dendritic cells which are widely represented
throughout all the tissues play likewise an important role
in SLE. Experimental studies in mice show that the deple-
tion of DCs in mice leads to a CD4 T cell-dependent self-
tolerance break and induces autoimmunity [41]. It is
important to mention that especially particular types of
DCs such as myeloid DCs (mDCs), regulatory DCs (rDCs),
and plasmacytoid DCs (pDCs) are involved in the develop-
ment of the disease [42–44]. pDCs that can be isolated from
blood or generated in vitro from humanmonocytes or mouse
bone marrow stimulated with Flt-3 ligand (Flt-3L). In con-
trast to mDCs, pDCs do ingest apoptotic and necrotic mate-
rial only in form of immune complexes and produce large
amounts of type I IFN which is involved in the pathogenesis
of SLE [42, 45, 46].
One of the challenges in immunology over the past
decades has been to unravel the mechanisms of immunolog-
ical tolerance. The tolerance checkpoints control lymphocyte
responses, their selection, activation, and neutralization.
All these features are necessary to enable proper immune
responses and to avoid autoimmunity. Recently, epigenetic
modulations executed by microRNAs (miRNAs), that intro-
duce the changes in gene expression, move the importance of
regulatory processes to the fore. They allow regulation of
immunological functions of cell subsets orchestrating innate
immune responses and T cells as well as B cell and plasma
cell diﬀerentiation [47]. Consequently, miRNAs may play
an important role in altering inﬂammation and development
of autoimmune disorders. Changes in miRNA expression
and miRNA-mediated regulation of autoimmune genes
may be a reason for susceptibility to complex autoimmune
diseases such as SLE. MicroRNA-mediated inhibition of gene
expression has not without a reason gained importance in
both regulating autoimmune-relevant responses and modu-
lating inﬂammatory responses (Figure 1). miRs have the
unique capacity to repress the expression of target transcripts
rapidly and precisely to prevent the development of anti-
inﬂammatory responses and balance between eﬀective host
defense and autoimmunity.
3. Biogenesis of MicroRNA
Mature microRNAs are usually 19–22 nucleotides in length
and regulate gene expression in posttranscriptional level.
Their binding sites are normally located in 3′ untranslated
region (UTR) of target mRNA. The genes encoding the pri-
mary transcripts (pri-miRNA) of microRNA can be found
in intergenic regions of the genome or within introns of
protein-coding genes. First, pri-miRNA is produced by
RNA polymerase II and III in the form of long tran-
scripts containing hairpin stem-loop structure [48–50].
Secondly, the maturation process of pri-miRNA is mediated
by nuclear RNase III Drosha and its cofactor DGCR8
(DiGeorge syndrome chromosomal region 8) [51]. They
form so-called microprocessor complex [52] that releases
65–70-nucleotide-long small hairpin precursor microRNA
(pre-miRNA) from stem-loop structure [53]. Followed by
processing of pre-miRNA by Drosha, pre-miRNA is
exported into the cytoplasm by mediating of Exportin 5
(EXP5) protein and a cofactor called Ran-GTP [54–56]. In
addition, it was reported that downregulation of EXP5
reduces the translocation of pre-miRNA into cytoplasm but
does not enhance accumulation of the pre-miRNA in the
nucleus. This ﬁnding suggests that the EXP5 protects the
microRNA from exonucleolytic digestion in the nucleus
[55]. In the cytoplasm, other enzyme called Dicer cleaves
the pre-miRNA and produces a small double-strand RNA
(dsRNA) [57, 58]. Subsequently, dsRNA is loaded onto Argo-
naut (Ago) protein to form RNA-induced silencing complex
(RISC) [59, 60] in order to unwind the dsRNA and produce
mature guide strand [61]. There are eight Ago proteins iden-
tiﬁed in human [62] but only four [1–4] are able to load
miRNA or siRNA regardless of their structure [63, 64].
miR-RISC complex is an eﬀector that mediates silencing
process [65]. Within this complex, the seed region of miRNA
(2–8 nucleotides) is a most critical region for selecting the
mRNA targets [66]. In this form, microRNAs have the ability
to mediate pretranslational, cotranslational, or posttransla-
tional silencing [67]. Apart from the canonical pathway of
miRNA processing, the noncanonical (microprocessor- or
Dicer-independent) pathway have been described [68–71].
This alternative mechanism was ﬁrst seen in mitron-
processing pathway [72, 73] where pre-RNA is produced by
mRNA splicing and is independent of Drosha [70, 71]. Some
small RNAs may also originate from other noncoding RNAs
such as small nuclear RNAs [74], tRNAs [70], and small viral
RNAs [75]. The biogenesis of these RNAs is also independent
of Drosha but still dependent on Dicer.
4. MicroRNA in SLE and LN
MicroRNA expression patterns in lupus-prone mice and
lupus patients indicate the clinical relevance of miRNAs in
SLE [76, 77]. In addition, anti-Su autoantibodies, which can
be detected in SLE patients, were shown to bind to the critical
catalytic enzyme in miRNA pathways (Argonaute 1–4 and
Dicer) [78, 79]. A direct link between SLE and miRNA
expression was ﬁrst investigated by Dai et al. who identiﬁed
diﬀerent expression patterns in a few miRNAs in peripheral
blood mononuclear cells (PBMCs) from SLE patients com-
pared to healthy controls [76]. In the last years, it has been
clearly recognized that SLE patients display distinct expres-
sion patterns of miRNAs including circulating miRs, which
need to be correlated with the aspects of the disease develop-
ment and progression [80–87]. Some microRNAs such as
miR-371-5p, miR-423-5p, miR-638, miR-1224-3p, and
miR-663 were found to be conserved and clearly regulated
in the PBMCs of lupus nephritis patients across patient
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groups of diﬀerent races [87]. Another comprehensive study
of human lupus nephritis identiﬁed 66 miRs that were diﬀer-
entially expressed between patients with lupus nephritis and
healthy controls [88]. Also, more precise correlations were
performed recently. Vinuesa et al. computationally analyzed
72 lupus susceptibility genes and showed that most genes
involved in the pathogenesis of the disease contain potential
multiple target sites for over 140 conserved in mammal’s
microRNAs [89]. Three miRNAs (miR-181, miR-186, and
miR-590-3p) are predicted to target over 50% of all lupus sus-
ceptibility genes. Some of the miRs such as miR-181, miR-
186, and miR-590-3 are believed to be strongly associated
with the predisposition to the disease [89]. The same study
predicted single miR-495, which belongs to the miR-329 gene
cluster comprised of 11 miRNAs (miR-134, miR-154, miR-
299, miR-329, miR-376, miR-376c, miR-494, miR-495,
miR-543, and miR-758) to regulate multiple lupus genes.
Moreover, microRNAs such as miR-216, miR-411, miR-
296-3p, and miR-361 5p targeted more than 10% of SLE
genes [89]. In another cohort of patients, Stagakis et al. iden-
tiﬁed 27 dysregulated miRNAs in the PBMCs of SLE patients,
2 of which were consistent with miRNAs identiﬁed by
Dai et al. and 19 of which correlated with disease activity
[76, 90]. Eight of the latter appeared to be diﬀerentially
expressed in T cells and four of them were deregulated in B
cells. Another study showed that 7 abnormally expressed
miRNAs (miR-145, miR-224, miR-150, miR-483-5p, miR-
513-5p, miR-516a-5p, and miR-629) are present in SLE T
cells compared to healthy controls [91]. Hyperactive T cells
from patients seem to display distinct microRNA signature
than T cells from healthy patients [90, 92, 93]. All these
ﬁndings are well-recognized pieces of evidence of miRNA-
mediated pathogenesis of SLE. However, the extensive analy-
sis of the expression levels of microRNAs in SLE patients in
comparison with healthy individuals did not necessarily
reveal any pattern of dysregulated microRNA. The variations
observed within populations which were investigated as well
as diﬀerent detection methods disable a speciﬁc comparison
between the results from single studies. This may explain
why some investigations showed less cohesive microRNA
expression results. Serum level of miR-223 in SLE patients
from diﬀerent ethnic groups was shown increased in PBMCs
from Chinese SLE patients [94] and signiﬁcantly downregu-
lated in European patients with active lupus nephritis [83].
Apart from correlations and computational analysis, the
role of miRNAs in the development of autoimmune diseases
has been demonstrated in various experimental studies.
Deletion of Drosha or Dicer in T cells evidenced the impor-
tant function of miRNA in T lymphocytes [95–97]. The
absence of miRs was associated with decreased T cell number
and increased inﬂammation. This phenomenon could be
explained by deregulated Tregs suppressive phenotype.
For instance, Dicer deﬁciency in Treg cells leads to the
development of systemic autoimmune diseases [98, 99].
SLE-prone MRL/lpr lupus was shown to display reduced
Treg-maintained suppressive activity due to spontaneous
Dicer insuﬃciency in these cells [100]. Moreover, the exper-
imental studies with B cell-speciﬁc knockouts of Dicer have
shown that microRNAs not only play a role in B cell-
maintained immunity but also are involved in the develop-
ment of autoimmune responses as well [101–104].
Various experimental studies reveal that microRNAs are
diﬀerentially expressed in male and female [105, 106]. This
information seems to be relevant since females have higher
incidence of SLE as compared to male. Furthermore, epide-
miological and clinical data demonstrate that unlike males,
the females tend to develop severe disease [107]. This sex-
diﬀerential susceptibility to SLE may be inﬂuenced by genes
expressed on sex chromosomes and the level of sex hormones
[108–110]. Several microRNAs have already been described
to be aﬀected by the estrogen levels [111–113]. Moreover,
the administration of the primary female sex hormone estro-
gen to males that underwent orchiectomy aﬀects the expres-
sion of lupus-relevant microRNAs [114]. The susceptibility
to SLE observed in female may be supported by the positive
correlation of estrogen levels with manifestation of the dis-
ease. However, since estrogen regulates the inﬂammatory
cytokines and interferon as well as the activation of B cells,
its exact direct or indirect eﬀects on microRNAs and autoim-
munity remain elusive [115–117]. Moreover, variable expres-
sion of some genes in females is inﬂuenced by the process of
X-chromosome inactivation (XCI). The extra X chromosome
in females undergoes this process during embryogenesis.
However, over 15% of human X-linked genes remain to be
expressed from the inactive X chromosome [118]. The
impact of such escape genes in sexually dimorphic disease
risk may display signiﬁcant eﬀects on immune responses
[119]. For instance, the expression of TLR7 and CD40LG
that are located on X-chromosome was reported to be
increased in SLE patients [120, 121]. On a cellular level, these
sex-based diﬀerences are evidenced in pDC signaling. Laﬀont
et al. showed that pDCs from women display enhanced
TLR7-mediated IFN-α production as compared with same
cells isolated from males. The authors linked these ﬁndings
to both estrogen levels that promote innate functions of
pDCs and human X-linked genes [122].
5. MicroRNA Regulating Innate Immune
Responses Involved in Development of SLE
It is not surprising that various SLE-relevant processes such
as proinﬂammatory cytokine production, cell death, and
antigen presentation can be aﬀected by microRNAs. How-
ever, many of the microRNAs that were found showed diﬀer-
ent expression pattern between lupus patients and healthy
controls in peripheral blood mononuclear cells (PBMCs)
may be involved in regulation of interferon (IFN) type I path-
way [87, 123]. For instance, the expression of miR-146a was
shown to correlate with the SLE disease activity and IFN sig-
naling by targeting IRF5 and STAT1 which were both
described as important genetic factors in the development
of SLE [123]. In addition, changes in miR-146a expression
were associated with dysregulated IFN responses. Regulation
of transcription factors IRF5 and STAT1 by this microRNA
was conﬁrmed. Furthermore, miR-146a was shown to down-
regulate TRAF6-, IRAK1-, and IRAK2-mediated inﬂamma-
tory signals in macrophages and aﬀects the type I IFN
production in these cells [124]. Among all dendritic cells,
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pDCs were described to play a crucial role in SLE develop-
ment due to their ability to secrete a signiﬁcant amount of
type I IFN upon TLR7/9 stimulation [125]. Consequently,
in plasmacytoid dendritic cells (pDCs), upregulated levels
of microRNA-146a were shown upon TLR7/9 stimulation.
Moreover, this microRNA plays a role in pDC survival
[126]. These recent studies could indeed evidence miR-146a
as a key regulator of pDC function. This hypothesis was
already supported by the study showing that overexpression
of miR-146a in the CAL-1 pDC cell line triggers apoptosis,
impaired TLR7-dependent inﬂammatory processes, and
decreased the ability of pDCs to drive CD4+ T cells prolifer-
ation [126]. In addition, a recent study identiﬁed a new key
player in pDC signaling. It reported that type I IFN inhibits
the maturation of miR-146a through the upregulation of
MCPIP-1 and that this phenomenon contributes to the
uncontrolled inﬂammation and excessive inﬂammatory gene
expression in SLE [127]. In silico investigations suggested
further potential microRNAs that might target the INF path-
way. Notably, some of these microRNAs appeared to be dys-
regulated in PBMCs of SLE patients [87].
Another crucial pathway in the development of SLE is
NF-κB-related inﬂammation. Let-7 miRNAs were shown to
modulate the activation of NF-κB by targeting another SLE-
relevant negative regulator of innate responses, namely,
TNFAIP3 [128]. Overexpression of Let-7 miRNAs led to
increased TNFα stimulation and production of cytokines in
HEK293T cells. In addition, the expression of Let-7 miRNAs
was signiﬁcantly upregulated, and the TNFAIP3 level was
remarkably downregulated in samples from LN patients
compared to control samples suggesting another potential
target for therapeutic intervention [128]. Recently, Wang
et al. identiﬁed miR-663a/miR-423-5p as microRNA modu-
lating the activation of NF-κB by binding to TNIP2. This
novel miR was suggested to be involved in the pathogenesis
of lupus nephritis [129]. Levels of miR-663a/miR-423-5p
were high in kidney tissues from LN patients as compared
to kidney tissues from SLE patients without signiﬁcant renal
phenotype and normal tissues. Consequently, TNIP2 was
downregulated in tissues from LN patients. Consistent with
the data, an experimental pristane-induced model of LN
was characterized by increased levels of miR-663a/miR-
423-5p and reduction of TNIP2 transcript in response to
renal injury. miR-663a/miR-423-5p mimics and inhibitors
triggered decrease and increase of TNIP2 levels, which,
respectively, might provide new therapeutic targets for LN
treatment [129]. One of the best-characterized miRs involved
in both NF-κB- and IFN-dependent inﬂammatory and auto-
immune conditions is miR-155. It was shown to regulate
innate immune response by inhibiting MyD88 and TAB2-
dependent inﬂammatory responses [130, 131]. Interestingly,
miR-155 upregulates the type I interferon signaling in mac-
rophages by inhibiting the suppressor of cytokine signaling-
1 (SOCS-1) [132]. As previously mentioned, the type I IFN
is one of the key cytokines promoting the development of
SLE. Surprisingly, miR-155∗ that originates from the same
precursor and is also induced by TLR7 through the c-Jun
N-terminal kinase pathway had opposite eﬀects on the regu-
lation of type I interferon production of pDC [133]. While
early-stage-produced miR-155∗ increased interferon-α/β
expression by suppressing IRAKM, late-stage-expressed
miR-155 inhibited their expression by targeting TAB2
[133]. This suggests their cooperative involvement in pDC
function and activation. Moreover, miR-155-deﬁcient mice
with pristine-induced lupus model displayed signiﬁcantly
lower serum levels of autoantibodies and had less pulmonary
involvement and renal disease compared to wild types. These
mice showed a less prominent T cell response and lower
expression of genes responsible for disease development,
including interferon type I dependent genes [134]. Another
study that investigated the potential of miR-155 in SLE
showed that miR-155 suppresses autoimmunity through
transcriptional repression of PU.1 and TNF-α, which in turn
suppresses BAFF and CD19 protein expression. miR-155
decreased, therefore, the proportion of BAFF-expressing B
cells and CD19 protein expression [110]. MicroRNA-155
expression was also signiﬁcantly increased during the devel-
opment of diﬀuse alveolar hemorrhage (DAH) which is rare
but life-threatening complication of SLE. DAH progression
in pristane-induced lupus was reduced in miR-155-deﬁcient
mice as well as by in vivo treatment with a miR-155 antago-
mir [135]. These results suggest that antagonizing miR-155
might be beneﬁcial for SLE patients with complications such
as acute lung inﬂammation. A recent experimental study that
also used the model of pristane-induced inﬂammation iden-
tiﬁed miR-302d as a key regulator of type I IFN-driven gene
expression. miR-302d targets IRF9, regulates interferon-
stimulated genes (ISG) expression, and protects against auto-
immunity in mice [136]. Another IFN regulatory factor-8
(IRF-8), a crucial transcription factor for pDC development
and activation, was described as a target of miR-618. Upreg-
ulation of miR-618 can inhibit the development of pDCs
from CD34+ cells in vitro and interestingly also promote
their ability to secrete IFNα [137].
Other miRs were also described to aﬀect innate immune
responses by targeting SLE susceptibility genes. miR-3148
regulates expression of TLR7 by binding to its >3′UTR
[138]. Let-7c downregulates B lymphocyte-induced matura-
tion protein-1 (Blimp1) as well as suppressor of cytokine
signaling-1 (SOCS1) expression in dendritic cells, contribut-
ing to the extensive production if SLE-relevant proinﬂam-
matory cytokines [139].
6. MicroRNA Regulating Adaptive Immunity
Involved in Development of SLE
Many new studies focus on the miRNA-dependent mech-
anisms that regulate the signaling and development of T
cells and the imbalance of the T lymphocyte subsets have
been implicated in diﬀerent histological manifestations of
SLE. MicroRNAs seem to play an important role in the
T cell-mediated responses. For instance, miR-126 and miR-
148a are upregulated in T cells isolated from SLE patients
and aﬀect the DNA methylation by reducing the expres-
sion of DNA methyltransferase 1 (DNMT1) [140–142].
Moreover, high levels of miR-21, miR-148a [141], and miR-
29b [143] were shown to positively correlate with DNA
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hypomethylation in lupus CD4+ T cells, and suppression
of these miRs is beneﬁcial [141, 143]. High expression of
miR-21 has been shown to correlate with SLEDAI score
[90]. In CD4+ T cells and macrophages, miR-21-dependent
suppression of PDCD4 expression aﬀects proliferation, IL-
10, and CD40L expression and consequently promotes the
development of plasma cells and IgG production [90, 144].
Inhibition of another miR, namely, miR-142-3p/5p in
CD4+ T cells, which was observed also in SLE patients,
was associated with increased levels of IL-4, IL-10, CD40L,
and ICOS protein expression and could be linked to B cell
hyperactivity [145].
There is evidence that apart from interferon type I also
some cytokines and chemokines can have an active role in
the pathogenesis of SLE and contribute to the immune
imbalance in the disease. For instance, downregulation of
IL-2 production is one of the features observed in SLE path-
ogenesis and T cell-dependent production of IL-2 was shown
to be impaired in SLE patients [146]. IL-2 plays a dominant
role in immune tolerance and inﬂammatory responses and
is important in regulatory T cell maintenance [147]. The
low Il-2 production in T cells was linked to the expression
of miR-31 in SLE patients [148]. Further investigations
demonstrated that miR-31 negatively regulates FOXP3
expression [149]. A recent study reported that decreased
miR-200a-3p causes IL-2 hypoproduction in a lupus-prone
mouse and that low levels of miR-200a-3p aﬀect the binding
of the ZEB1-CtBP2 complex to the IL-2 promoter and sup-
press IL-2 production [150].
In the past few years, the classical T cell paradigm has
been expanded to include the proinﬂammatory Th17 cells,
which express of the transcription factor RORγt and inﬂu-
ence immunosuppressive regulatory T cells. Interleukin-17
(IL-17) produced by Th17 contributes to inﬂammatory
autoimmune diseases. Zhu et al. showed in their study that
miR-23b is downregulated in both inﬂammatory lesions of
humans with lupus and in the mouse models of lupus. The
study evidenced that miR-23b suppresses IL-17-, tumor
necrosis factor α- (TNF-α-) or IL-1β-induced NF-κB activa-
tion, and inﬂammatory cytokine expression by targeting
TGF-β-activated kinase 1/MAP3K7 binding protein 2
(TAB2), TAB3, and inhibitor of nuclear factor κ-B kinase
subunit α (IKK-α) [151]. Recently, miR-873 expression was
shown to be signiﬁcantly upregulated in patients with SLE
[152]. Its expression was positively associated with the dis-
ease severity. CD4+ T cells, especially the Th17 subset, were
found to be the major source of miR-873, and its function
was linked to diﬀerentiation of CD4+ T cells into the Th17
lineage by downregulating the inhibitor of Th17 cell diﬀeren-
tiation in a forkhead box O1- (Foxo1-) dependent manner.
Furthermore, in vivo inhibition of miR-873 signiﬁcantly
reduced the disease severity in MRL/lpr mice [152]. Also,
miR-30a that is downregulated in human and mouse
SLE inhibits IL-17-mediated NF-κB and MAPK activation,
leading to a reduced production of inﬂammatory cytokines
and chemokines by targeting Traf3ip2 mRNA that is coding
for Act1 [153].
Studies in SLE patients and murine models have con-
ﬁrmed the importance of Th2 subsets in the pathogenesis
of SLE. Indeed, patients with lupus nephritis had signiﬁcantly
lower levels of Th1-cytokines than IL-4 and IL-10, suggesting
a clear shift towards the type 2 cytokine phenotype [154].
Moreover, the levels of the type 2 cytokine IL-10 correlated
with titers of anti-dsDNA antibodies [155]. miR-410 expres-
sion in T cells of SLE patients was decreased compared to
that in healthy controls [156]. Its function was associated
with the supersession of the STAT3 transcription activity
and was accomplished by binding directly to the 3 ′UTR of
STAT3 mRNA and regulating the expression of IL-10
[156]. Consequently, overexpression of miR-410 signiﬁcantly
reduced the expression levels of IL-10 [156]. Another study
identiﬁed miR-410 as a factor reducing the expression of
interleukin-6 and as a suppressor of LN-mediated renal
ﬁbrosis [157].
A downregulation of another miR, namely, miR-451a
reduced the enlargement of the spleen as well as the protein-
uria and immune complex deposits in SLEmouse model. The
deﬁciency of miR-451a abated numbers of CD4+CD69+ and
CD4+/CD8+ T cells and the levels of the serum cytokines
IL-17a and IL-4. The IFN regulatory factor (IRF) 8 was a
target of miR-451a in vitro and in vivo [158]. Overexpression
of miR-142-3p in monocyte-derived DCs (moDCs) caused
an increase of SLE-related cytokines, such as CCL2, CCL5,
CXCL8, IL-6, and TNF-α, and resulted in increased inﬁltra-
tion of CD4+ T cells and in suppression of Tregs in DC-
CD4(+) T cell coculture, whereas the proliferation of CD4+
T cells was not altered [159]. This strong regulation of the
proinﬂammatory function, as well as the attraction of a
signiﬁcant number of CD4+ T cells, was associated with
changed expression of miR-142-3p. miR-125a was shown
to be substantial for signaling of another decisive T cell sub-
population. It stabilizes both the commitment and immuno-
regulatory capacity of Treg cells. In miR-125a-deﬁcient mice,
the balance shifts from immune suppression to inﬂamma-
tion. miR-125a suppresses several eﬀector T cell factors
including Stat3, IFNg, and IL-13. Moreover, its chemically
synthesized analog had the potential to reprogramme the
Treg-mediated immune homeostasis [160]. Some of the
miRs targeting innate and adaptive immune responses were
included in Table 1.
As already mentioned before, also B cells which are the
source for autoantibodies play a central role in disease path-
ogenesis and progression. SLE patients show abnormal B cell
activation and diﬀerentiation to memory or plasma eﬀector
cells and consequently secretion of autoantibodies that are
fundamental in the pathogenesis of local inﬂammation and
organ injury. Diverse proﬁling studies performed on hemato-
poietic cell lineage showed the diﬀerential regulation of
microRNAs in B cells. Notably, miR-16, miR-30c, miR-34a,
miR-142-3 and 5p, miR-150, miR-155, miR-181, and miR-
223 were found to be substantial in B cells [161–164]. Some
of these microRNAs such as miR-142-3p and 5p were postu-
lated to be involved in antibody production [145]. Moreover,
deep-sequencing study shows the expression of 232 known
microRNAs and found B cell stage-speciﬁc proﬁles [165].
The authors conﬁrmed the previous results and investigated
the expression proﬁles of miR-150, miR-146a, miR-155,
and miR-181 in detail. Furthermore, they identiﬁed and
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validated 45 novel microRNAs expressed in developing B
cells. Other previously mentioned study that investigated T
and B cell populations in SLE showed seven microRNAs with
diﬀerential expression in peripheral B cells in patients with
SLE, compared to healthy controls [90]. These microRNAs
include miR-150, miR-16, miR-15a, miR-155, miR-25, miR-
21, and miR-106b. Notably, miR-21 is also overexpressed in
splenic B cells from two mouse lupus models [141, 166]. Sev-
eral studies described function of particular microRNAs in
lupus B cells and some of the described microRNAs were
associated with regulation of SLE susceptibility genes. For
instance, an increase of miR-30a expression and its binding
to the 3′-UTR of Lyn mRNA aﬀected the phenotype of B cells
in SLE patients [167]. Lyn, which was previously described as
a crucial negative regulator of B cell activation, proliferation,
and antibody production, is downregulated in B cells isolated
from SLE patients [168, 169]. A similar function was
described for miR-1246. The authors described that the
expression of miR-1246 was signiﬁcantly decreased in B cells
from SLE patients. miR-1246 speciﬁcally targeted the EBF1 3
′-UTR region of mRNA and regulated the expression of
EBF1 and consequently enhanced B cell function by increas-
ing the number of B cell surface costimulatory molecules
CD40, CD80, and CD86 [170]. Other miRs expressed in B
cells such as miR-155 and miR-181b downregulate the
activation-induced cytidine deaminase (AID) [171–173]
which plays important role in the regulation of B cell activity.
Nevertheless, the exact mechanism how miR-155 and miR-
181b regulate the function of AID remains unclear. Changes
in miR-15a expression level were linked to its role in bal-
ancing diﬀerent B cell subsets such as immunosuppressive
B-10 cells, conventional B-2 cells, and regulatory B-1 cell
signaling and autoantibody production [174]. A study of
Duroux-Richard et al. identiﬁed a miRNA signature of puri-
ﬁed B cell subsets from renal and nonrenal severe SLE
patients. Further statistical analysis of the miRNAs that were
diﬀerentially expressed between all groups revealed that only
a small number of miRNAs are signiﬁcantly deregulated in
Table 1: MicroRNAs involved in the pathogenesis of systemic lupus erythematosus.
Cells miR(s) Target(s) Function(s) Ref
DCs
miR-126 Tsc-1 Negative regulation of mTOR-miR-126-VEGFR2-axis [178]
miR-155 Ship1, KPC1 Intervenes in CD40 expression [179]
miR-146a
STAT1, IRF5,
IRAK1, TRAF6
Negative regulator of type I IFN pathway [123]
Let-7c Blimp1 Regulates SOCS1 and IL-6 [139]
B cells
miR-30a Lyn Contributes to B cell proliferation and the production of IgG antibodies [167]
miR-155 Pu.1 Decreases the level of TNF alpha production [110]
miR-181b AID Less CSR in activated B cells [173]
miR-150 c-Myb Involved in lymphocyte development and response [180]
miR-34a Foxp1 Involved in the regulation of B cell development [181]
miR-125b Blimp-1, Irf4 Contributes to B lymphocyte diversiﬁcation in GC [182]
miR-93 AID Less class switch recombination in activated B cells [173]
miR-21 PDCD4 Decreased the Fas receptor-expressing B cells [166]
miR-1246 EBF1 Increase of miR-1246 expression results in less responsiveness of B cells [170]
T Cell
miR-126 DNMT1 T and B cell hyperactivity, regulates DNA methylation in CD4+ T cells [140]
miR-29b DNMT1, Sp1 More CD11a and CD70, unusually high global DNA hypomethylation in T cells [143]
miR-148a DNMT1 More LFA1 and CD70, increase DNA hypomethylation in T cells [141]
miR-21 RASGRP1 Activated T cell and enhanced proliferation [141]
miR-142-3p CD84, IL-10 Increased T cell activity and higher IgG production [145]
miR-142-5p SAP Increased T cell activity and higher IgG production [145]
miR-31 RhoA More production of IL-12 by changing NF-AT expression [148]
miR-125a
KLF13
(RFLAT-1)
Negative regulator of the feedback loop of KLF13 and RANTES production in the activated
T cell pathway
[149]
miR-224 AIP5 Speeds activation-induced cell death in T cells [93]
miR-155 CD62L Important for Treg cell development and function [100]
miR-873 Foxo1 Eases diﬀerentiation of CD4+ T cells into Th17 lineage [152]
miR-410 IL-6 Lower IL-6 expression, less ﬁbrosis [157]
miR-125a
STAT3, IL-13,
IFNg
Steadies the commitment and immunoregulatory capacity of Treg cells [160]
miR-181a
SHP-2, PTPN22,
DUSP5, DUSP6
Functions as an intrinsic antigen sensitivity “rheostat” throughout T cell development [183]
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the context of SLE [175]. This argument is supported by
the transcriptional study of CD19+ B cells that reports
weak diﬀerences between SLE patients and controls and
pointing out the similarities at the transcriptomic level
between normal and lupus B cells [176]. The diﬀerences
between patients and controls appear quite weak with only
14 genes out of 18271 that appear to be diﬀerentially
expressed (PMEPA1, TLR10, TRAF3IP2, LDOC1L, CD1C,
and EGR1) [176]. Recently, cyclinD3 (CCND3) was sug-
gested to play an important role in B cell proliferation,
development, and diﬀerentiation. The activation of TLR7
increased CCND3 expression via the downregulation of
miR-15b in B cells [177].
7. Conclusions
Tremendous eﬀorts have been made to explore the crucial
mechanisms responsible for the initiation and development
of the autoimmunity. Although signiﬁcant progress has
taken place, there is still a strong need for reliable biomarkers
for diagnosis and monitoring of the disease. Moreover, novel,
eﬃcient, and safe therapies need to be developed. Under-
standing of the role of microRNAs in the regulation of abnor-
mal and imbalanced activation of immune responses may
represent the new possibilities for development of better
monitoring and therapies.
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